Back to School: How biopharma can reboot drug development. Access exclusive analysis here
ADLR gained $0.73 (19%) to $4.48 on Wednesday after it entered into an
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury